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Abstract
BACKGROUND & AIMS—Studies of liver cancer risk in recipients of solid organ transplants 
have generally been small, yielding mixed results, and little is known about biliary tract cancers 
among transplant recipients.
METHODS—We identified incident hepatobiliary cancers among 201,549 US recipients of solid 
organs, from 1987 through 2008, by linking data from the US transplant registry with 15 cancer 
registries. We calculated standardized incidence ratios (SIRs), comparing risk relative to the 
general population. We also calculated incidence rate ratios (RRs), comparing risk for 
hepatocellular carcinoma (HCC) and total (intrahepatic and extrahepatic) cholangiocarcinoma 
among subgroups of recipients.
RESULTS—Of transplant recipients, 165 developed hepatobiliary cancers (SIR, 1.2; 95% 
confidence interval [CI], 1.0–1.4). HCC risk was increased among liver recipients (SIR, 1.5; 95% 
CI, 1.0–2.2), especially 5 or more y after transplant (SIR, 1.8; 95% CI, 1.0–3.0). 
Cholangiocarcinoma was increased among liver (SIR, 2.9; 95% CI,1.6–4.8) and kidney recipients 
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(SIR, 2.1; 95% CI, 1.3–3.1). HCC was associated with hepatitis B virus (RR, 3.2; 95% CI, 1.3–
6.9), hepatitis C virus (RR, 10; 95% CI, 5.9–16.9), and non-insulin-dependent diabetes (RR, 2.5; 
95% CI, 1.2–4.8). Cholangiocarcinoma was associated with azathioprine maintenance therapy 
(RR, 2.0; 95% CI, 1.1–3.7). Among liver recipients, primary sclerosing cholangitis (PSC) was 
associated with increased risk of cholangiocarcinoma, compared to the general population (SIR, 
21; 95% CI, 8.2–42) and compared to liver recipients without PSC (RR, 12.3; 95% CI, 4.1–36.4).
CONCLUSIONS—Risks for liver and biliary tract cancer are increased among organ transplant 
recipients. Risk factors for these cancers include medical conditions and medications taken by 
recipients.
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Liver cancer, including hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC), is the third leading cause of cancer deaths worldwide.1 In the 
US, the incidence of HCC,2 ICC,3 and extrahepatic cholangiocarcinoma (ECC)4 is 
increasing, together with hepatobiliary cancer mortality rates.5
Liver cancers may be elevated after solid organ transplantation, which is associated with 
increased risk of infections-related cancers.6 Immunosuppressive drugs used to prevent 
organ rejection suppress immunologic control of infections and create imbalances in 
immune response. Biliary tract cancers have also been associated with hepatitis B and C 
viruses (HBV, HCV)7,8 and may therefore be elevated in transplant recipients.
Previous studies of liver cancer risk in transplant recipients have produced mixed results.9,10 
Most studies included few (<20) liver cancer cases and did not evaluate individual 
hepatobiliary cancers, especially biliary tract cancers. The purpose of the current study was 
to compare the incidence of individual hepatobiliary cancers in solid organ transplant 
recipients relative to the general population and determine risk factors for these cancers 
among transplant recipients.
Materials and Methods
Solid Organ Transplant Recipients
With the addition of the Utah and Florida cancer registries, the recently described6 US 
Transplant Cancer Match Study currently accounts for ~43% of the US transplant 
population through 2008. In brief, the Scientific Registry of Transplant Recipients (SRTR), 
which has data from all US solid organ transplant recipients since 1987, was matched with 
15 US population-based cancer registries. The study was approved by human subjects 
committees at the National Cancer Institute and participating cancer registries as required.
Among recipients, we evaluated follow-up from transplantation (or start of cancer registry 
coverage, whichever came last) to the first of: 1) hepatobiliary malignancy diagnosis; 2) 
transplanted organ failure; 3) subsequent transplant; 4) death; 5) end of cancer registry 
coverage. HIV-infected recipients (<300) were excluded because they are infection-
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immunosuppressed. Hepatobiliary cancers were identified using linked cancer registry data, 
based on International Classification of Disease for Oncology (ICD-O-3) topography codes 
C22 (primary liver cancer), C23.9 (gallbladder cancer), and C24 (other biliary tract cancers), 
with further refinements described in Supplemental Table 1. Major cancers of interest 
included HCC, total cholangiocarcinoma (ICC and ECC), gallbladder cancer, and ampulla 
of Vater cancer.
We initially identified 1238 hepatobiliary cancers among solid organ transplant recipients; 
165 (13%) were included in the final analysis (Table 1) after the following exclusions. First, 
we excluded 1062 hepatobiliary cancer cases diagnosed within 6 months of a liver transplant 
(Supplemental Figure 1) since hepatobiliary cancers diagnosed so soon after a liver 
transplant were likely present in the explanted liver at the time of transplantation but looked 
like they occurred after transplant due to small errors in diagnosis date (median time to 
cancer diagnosis for these cases=7 days). Second, since some cases classified as incident in 
fact actually reflect regrowth of the original tumor, we excluded recipients noted by the 
transplant registry as having recurrent malignancy (N=632, of whom only 11 had 
hepatobiliary cancer documented in the cancer registry).
Ninety-two percent of initially identified HCC cases (949/1035) were thus dropped as 
prevalent or recurrent, compared to 60% of ICC cases (42/70), 50% of ECC cases (14/28), 
71% of gallbladder cancer cases (20/28), and 0% ampulla of Vater cases (0/12) (Table 1). 
We did not exclude cancers in individuals with an SRTR or cancer registry indication of 
liver cancer diagnosed at or before transplant because these individuals may have developed 
a new cancer. The final analytic cohort included 201,549 transplant recipients.
Statistical Analyses
We compared hepatobiliary cancer risk in solid organ transplant recipients to the general 
population using standardized incidence ratios (SIRs).6 We stratified SIRs by transplanted 
organ (liver versus non-liver) and time since transplant, testing for linear trend using Poisson 
regression. Since the gallbladder is removed from donor livers, the SIR calculations for 
gallbladder cancer were restricted to non-liver transplant recipients.
Risk factors for developing HCC and total cholangiocarcinoma, the most common 
hepatobiliary subtypes, after transplantation were examined via Poisson regression-based 
incidence rate ratios (RRs). All models were adjusted for age at transplant (continuous), 
gender, race/ethnicity (non-Hispanic white versus other), and transplant organ (liver only 
versus other).
Potential risk factors included HBV, HCV, body mass index (BMI), diabetes, 
immunosuppressive therapies, and reason for transplant. Only data from 1994 onward were 
used to establish HBV or HCV status because few data were available before 1994. Subjects 
were classified as having an active HBV infection if they were seropositive for HBV surface 
antigen (HBsAg), resolved infection if seropositive for antibody to HBV core antigen (anti-
HBc) but negative/unknown for HBsAg, uninfected if seronegative for either antigen and the 
other marker was negative/unknown, and unknown if serostatus was unknown for both 
antigens (see Supplemental Methods).
Koshiol et al. Page 3













Because the dataset included children (ages 2–19 years) and adults (ages ≥20 years), BMI 
was defined as follows (adults, children): underweight (15–18.4 kg/m2, <5th percentile) 
normal (18.5–24.9 kg/m2, 5th–85th percentile) overweight (25.0–29.9 kg/m2, 85–95th 
percentile) obese (≥30.0 kg/m2, ≥95th percentile).
We conducted sensitivity analyses for the risk factors to address concerns over the potential 
presence of residual prevalent cancers despite the exclusions described above. We excluded: 
1) all HCCs (N=5) and cholangiocarcinomas (N=2) diagnosed within 6 months of transplant 
regardless of transplanted organ; 2) all individuals flagged in the SRTR and/or cancer 
registry as having liver cancer at/before transplantation (10 HCC, five 
cholangiocarcinomas); 3) cancers that developed among liver transplant recipients (31 HCC, 
14 cholangiocarcinomas).
Results
The median time between transplant and diagnosis for the 165 hepatobiliary cancer cases 
was 4.2 years. Most cases were HCC (52.1%), followed by ICC (17.0%), ECC (8.5%), 
ampulla of Vater cancer (7.3%), and gallbladder cancer (4.8%); 10.3% were other tumor 
types (Supplemental Table 1). No cases had HBV- or HCV-positive donors.
The median age of hepatobiliary cancer cases and non-cases was similar (45 versus 47 
years), as was the distribution of race/ethnicity and BMI (Table 2). Hepatobiliary cancer 
cases were more likely male and liver recipients than non-cases. The median follow-up for 
the cohort was 3.5 years.
Transplant recipients had higher risk of hepatobiliary cancers than the general population 
(SIR,1.2; 95%CI,1.0–1.4). The HCC risk was not elevated for all solid organ transplant 
recipients (Table 3) or non-liver recipients (SIR,0.9; 95%CI,0.7–1.1) but was elevated 
among liver recipients (SIR,1.5; 95%CI,1.0–2.2). In contrast, risk tended to be increased for 
biliary tract cancers, especially ICC. Risk of cholangiocarcinoma was elevated in liver (SIR,
2.9; 95%CI,1.6–4.8) and non-liver (SIR,1.8; 95%CI,1.2–2.6) recipients (Table 3), especially 
kidney recipients (SIR, 2.1; 95%CI,1.3–3.1). Among non-liver recipients, risk for 
gallbladder cancer was similar to the general population (SIR,0.8; 95%CI,0.3–1.6). Ampulla 
of Vater cancer was elevated among non-liver recipients only (SIR,1.9; 95%CI,0.9–3.4) 
(Table 3).
HCC risk tended to increase with time since transplant among all transplant recipients 
(Figure 1, p-trend, 0.04) and was borderline elevated ≥5 years after transplant among liver 
recipients (SIR:1.8; 95%CI:1.0–3.0). Risk for other hepatobiliary cancers did not 
consistently vary by time since transplant (Figure 1).
In a multivariate model, HCC risk increased with each additional 10 years of age (RR:1.5, 
95%CI:1.3–1.8), non-white race/ethnicity (RR:1.4, 95%CI:0.9–2.1), and liver 
transplantation (RR:2.0, 95%CI:1.3–3.1), and decreased with female gender (RR:0.3, 
95%CI:0.2–0.5). For cholangiocarcinoma, RRs were 1.6 (95%CI:1.3–2.1) for age (10 
years), 1.3 (95%CI:0.7–2.4) for non-white race/ethnicity, 1.8 (95%CI:0.9–3.4) for liver 
transplants, and 0.6 (95%CI: 0.3–1.2) for gender.
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Among all recipients, HCC risk was associated with HBV (RR,3.2; 95%CI,1.3–6.9), HCV 
(RR,10; 95%CI,5.9–17), and non-insulin-dependent diabetes (RR,2.5; 95%CI,1.2–4.8) 
(Table 4). Results were similar after adjusting for transplant year (Supplemental Table 2). 
Increasing BMI was associated with decreased HCC risk (p-trend, 0.03). Estimates of 
cholangiocarcinoma risk, although limited by small numbers, tended to increase with non-
insulin-dependent diabetes (RR,2.0; 95%CI,0.7–5.6) and obesity (RR,1.8; 95%CI,0.9–3.8). 
Only one cholangiocarcinoma case was HCV seropositive, and HCV was associated with 
reduced risk (RR,0.1; 95%CI,0.01–0.7). No immunosuppressive medications were 
associated with HCC (Table 4), but azathioprine was associated with increased 
cholangiocarcinoma risk (RR,2.0; 95%CI,1.1–3.7) with similar results after adjusting or 
stratifying by year of transplant (RR,2.1; 95%CI,0.9–4.6; Supplemental Table 3). Results for 
immunosuppressive medication use were similar when stratified by liver versus non-liver 
transplant (Supplemental Table 4). A model mutually adjusted for HBV, HCV, BMI, and 
diabetes produced RRs for HCC similar to those from the independent models 
(Supplemental Table 5). It was not possible to run a mutually adjusted model for 
cholangiocarcinoma given the small number of cases.
Among liver recipients, HCC risk was associated with noncholestatic liver disease (RR,13; 
95%CI,2.5–245) (Table 4), which includes cirrhosis due to HBV/HCV. Of 30 liver 
recipients with noncholestatic liver disease who developed HCC, 70% had l HBV-related 
liver disease (N=3), HCV (N=16), or both (N=2). Liver recipients with alcoholic liver 
disease as reason for transplant had borderline increased HCC risk compared to the general 
population (SIR,1.9; 95%CI,0.9–3.3).
Cholestatic liver disease was associated with increased cholangiocarcinoma risk (RR,9.1; 
95%CI,3.1–27) and noncholestatic liver disease with decreased risk (RR,0.2; 95%CI,0.1–
0.5) among liver recipients (Table 4). Cholestatic liver disease includes primary sclerosing 
cholangitis (PSC) and primary biliary cirrhosis (PBC). Of 14 liver recipients with 
cholangiocarcinoma, 7 (50%) had PSC and 1 (7%) had PBC. Additionally, 10 of these 14 
cholangiocarcinomas (five with PSC) were intrahepatic and therefore developed in the 
transplanted liver. The remaining four cholangiocarcinomas (two with PSC) were 
extrahepatic. The SIR for cholangiocarcinoma among liver recipients with PSC was 21 
(95%CI,8.2–42), and the RR for cholangiocarcinoma among PSC versus non-PSC liver 
recipients was 12 (95%CI,4.1–36). However, after excluding people with PSC, 
cholangiocarcinoma risk remained elevated among transplant recipients compared to the 
general population (SIR,1.7; 95%CI,1.4–2.4).
Among kidney recipients (Table 4), HCC risk was associated with diabetes (RR,2.4; 95%CI,
1.2–4.6) and inversely with glomerular disease (RR,0.3; 95%CI,0.1–0.9) as reason for 
transplant. Cholangiocarcinoma risk increased with polycystic kidney disease (RR,3.2; 
95%CI,1.2–7.8).
Excluding cancers diagnosed within 6 months of transplant and liver cancers at the time of 
transplant did not substantially change the results. For example, the RRs for active HBV and 
HCC with these exclusions were 3.3 (95%CI,1.2–7.1) and 4.4 (95%CI,1.6–9.7), 
respectively. Similarly, the RRs for azathioprine and cholangiocarcinoma were 2.0 (95%CI,
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1.0–3.8) and 1.8 (95%CI,0.9–3.5), respectively. Restricting to cancers that developed in 
non-liver recipients, the RRs were at least as strong as for all cases combined (e.g. RR:7.4, 
95%CI,2.2–18 for active HBV and HCC risk among non-liver recipients). The exception 
was BMI, although the trend was still inverse among non-liver recipients: RR=2.1 (95%CI,
0.5–5.8) for underweight, 0.45 (95%CI 0.2–0.9) for overweight, 0.62 (95%CI,0.2–1.4) for 
obese versus normal. For cholangiocarcinoma, the association with azathioprine was at least 
as strong among non-liver transplant recipients (RR 2.4; 95%CI,1.1–5.1) as overall.
Discussion
In >200,000 solid organ transplant recipients, we found increased risk of hepatobiliary 
cancers, including HCC among liver recipients, cholangiocarcinoma among liver and non-
liver recipients, and ampulla of Vater cancer among non-liver recipients.
The associations of HCC with HBV/HCV support a true increased risk since these infections 
are expected to cause incident HCC after transplant. Furthermore, 88% of the 165 cases 
occurred ≥1 year after transplantation, and >63% occurred ≥3 years after transplantation. 
The SIR for HCC among liver recipients was elevated ≥5 years after transplant, suggesting 
that the increased HCC risk is not due to prevalent cancers. While cancers may recur late 
after transplant, new cancers may also develop in the transplanted organ due to prolonged 
immunosuppression and/or HBV/HCV infection. For cholangiocarcinoma, incidence was 
elevated in both liver and kidney recipients compared to the general population, again 
supporting that the elevated SIRs reflect truly increased risk.
To our knowledge, this report presents the first evaluation of risk factors for 
cholangiocarcinoma after solid organ transplant, as well as an expanded analysis of risk 
factors for HCC. In addition to known risk factors for HCC and cholangiocarcinoma (e.g., 
HBV, HCV, non-insulin-dependent diabetes), there were novel findings, such as the 
associations with reason for transplant. For liver recipients, noncholestatic liver disease was 
associated with increased HCC risk. The inverse RR for noncholestatic liver disease and 
cholangiocarcinoma likely reflects that individuals with one condition typically do not have 
the other. To determine whether the increased HCC risk in transplant recipients is due 
entirely to a higher prevalence of HBV/HCV in this population or whether 
immunosuppression due to transplant also plays a role, we would ideally compare HBV/
HCV-positive transplant recipients with HBV/HCV-positive individuals in the general 
population. Unfortunately, we do not have HBV/HCV information for the general 
population.
Cholestatic liver disease (largely PSC) among liver recipients was strongly associated with 
increased cholangiocarcinoma risk. Cholangiocarcinoma develops in 10–30% of PSC 
patients (10-year cumulative incidence=7–9%).12 PSC is the 5th leading reason for 
transplantation in the US.13 Up to 25% of PSC patients who receive a liver transplant may 
develop recurrent PSC within 5–10 years.12 We do not have data on PSC recurrence in our 
study but found that PSC-related liver recipients were 20 times more likely than the general 
population to develop cholangiocarcinoma and 12 times more likely than other liver 
recipients. The increased risk of cholangiocarcinoma among transplant recipients was not 
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entirely due to PSC, however, since cholangiocarcinoma risk was elevated in kidney and 
liver recipients. It is unclear whether the increase in cholangiocarcinoma is due to a higher 
prevalence of risk factors among these patients or transplant-related immunosuppression.
Most cholangiocarcinoma cases in liver recipients were intrahepatic, reflecting 
carcinogenesis in the donor liver. For the four liver recipients with extrahepatic 
cholangiocarcinoma, it is unknown whether cancer developed in the donor extrahepatic duct 
joining the transplanted liver to the small intestine or in the stump of the native extrahepatic 
bile duct attached to the pancreas. Two cases had PSC as the reason for transplant. PSC 
patients commonly have hepaticojejunostomy rather than choledocholedochostomy and 
therefore do not have residual extrahepatic bile duct present after liver transplantation. Thus, 
the two extrahepatic cholangiocarcinoma cases with PSC are likely de novo cases.
Among kidney recipients, transplant-related glomerular disease was associated with 
decreased HCC risk, possibly due to chance. Polycystic kidney disease was associated with 
increased risk of cholangiocarcinoma, in accordance with several case reports of 
cholangiocarcinoma in individuals with polycystic kidney disease.14–16
The increased risk of cholangiocarcinoma associated with azathioprine was intriguing. PSC 
is treated with azathioprine, raising concerns over potential confounding due to treatment for 
PSC. However, the association was particularly strong among non-liver recipients. Although 
azathioprine is no longer a standard immunosuppressive medication, this association is not 
likely to reflect an effect of transplantation era since adjusting for year of transplant did not 
change the results. Azathioprine has been associated with skin cancer and lymphoma in 
solid organ transplant recipients.17,18 One recent study of 180 patients with autoimmune 
hepatitis found no significant association between azathioprine treatment and HCC 19 but 
had limited power since only 6 patients developed HCC. Given evidence that azathioprine is 
hepatotoxic in humans,20 it seems plausible that azathioprine may increase risk of 
cholangiocarcinoma in solid organ transplant recipients.
The trend toward decreasing HCC risk with increasing BMI was unexpected. The elevated 
RR for HCC in underweight transplant recipients may suggest that these patients had 
wasting due to the advanced stage of their disease. A recent study among liver transplant 
recipients found that the prevalence of muscle wasting (cachexia) increased dramatically 
with decreasing BMI.21 The observed association between BMI and risk of HCC may also 
reflect cachexia/muscle mass.
Data from previous studies of liver cancer after transplant are mixed.9–11,22–24 In our study, 
increased HCC risk of was limited to liver recipients, as seen previously.11 Few studies have 
reported on biliary tract cancer. Vajdic et al reported increased gallbladder cancer risk 
among kidney transplant recipients,22 and Engels et al reported increased intrahepatic 
cholangiocarcinoma and gallbladder cancer risk among all solid organ recipients.6 The 
Engels et al results were based on an earlier version of the SRTR/cancer matched data but, 
unlike the present analyses, did not incorporate exclusions to eliminate hepatobiliary cancers 
that may have been prevalent or recurrent.
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Strengths of this study include the representative population covering ~43% of transplant 
recipients and the largely complete case ascertainment through population-based cancer 
registries. Since liver cancer itself is an indication for liver transplant, we made special 
efforts to exclude prevalent cases. Although one recent study addressed this problem by 
assuming that all liver cancers reported after liver transplantation were not new cancers,23 
this approach would incorrectly exclude any true de novo tumors. Given 88% of the 
hepatobiliary cancers analyzed in this study were diagnosed >1 year after transplant, it 
seems likely that most were truly incident. Additionally, sensitivity analyses excluding all 
cases diagnosed within 6 months of transplant and all subjects with liver cancer at the time 
of transplant did not change the results. Finally, the study was large enough to conduct in-
depth analyses of HCC and cholangiocarcinoma. However, the number of cases was limited 
in some analyses, leading to imprecision in the point estimates. Some associations could be 
due to change given multiple comparisons. Furthermore, we had limited ability to control for 
potential confounders (e.g., smoking), HCV diagnosis was based only on antibody positivity 
without PCR confirmation, and we did not have data on dosage or duration of use of 
azathioprine or other immunosuppressive agents. Finally, we note that the US Transplant 
Cancer Match Study does not include all US solid organ transplant recipients, potentially 
limiting generalizability, although transplant recipients included in this study have been 
previously shown to be comparable to transplant recipients who were not included.6
In conclusion, this report provides the first in-depth analysis of both liver and biliary tract 
cancers after solid organ transplant. Its novelty stems from the large study population size, 
which allowed us to characterize the incidence of and risk factors for individual types of 
hepatobiliary cancers. Cholangiocarcinoma risk was elevated among liver and kidney 
recipients, and HCC risk was elevated among liver recipients. Consistent with studies in 
non-transplant populations, we found that conditions like viral hepatitis infection and 
diabetes were associated with increased risk. Given the success of new HCV treatments, our 
results highlight the importance of better therapies to treat HBV/HCV infections before 
transplant and to prevent or treat recurrent infection after transplant. Finally, although the 
results must be interpreted with caution, the associations with PSC and azathioprine use are 
intriguing and require further evaluation.
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Standardized incidence ratios for hepatobiliary cancer stratified by time since transplant.
Abbreviations: CI, confidence interval; SIR, standardized incidence ratio
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Table 2
Characteristics of the analytical transplant cohort
Hepatobiliary cancer
Yes (N=165) No (N=201384)
N % N %
Age at transplant, median (range) 45 (2–81) 47 (0–87)
Years of follow-up, median (range) 4.2 (0.02–16.1) 3.5 (0.003–22.2)
Gender
 Male 128 77.6 122644 60.9
 Female 37 22.4 78740 39.1
Race/ethnicity
 White, non-Hispanic 106 64.2 124770 62.0
 Black, non-Hispanic 30 18.2 34181 17.0
 Hispanic 21 12.7 31278 15.5
 Asian/Pacific Islander 8 4.8 11155 5.5
BMI/obesity*
 Underweight 7 4.9 8027 4.8
 Normal 67 46.9 71578 43.0
 Overweight 40 28.0 52218 31.4
 Obese 29 20.3 34676 20.8
Transplanted organ
 Liver 49 29.7 29023 14.4
 Kidney 81 49.1 117271 58.2
 Heart and/or lung 34 20.6 43333 21.5
 Other 1 0.6 11757 5.8
*
Numbers do not sum to total due to missing data.
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Table 3
Standardized incidence ratios for incident hepatobiliary malignancies (overall and by transplanted organ)
Transplant recipient group and outcome category
Overall
Observed Expected SIR 95% CI
All recipients
HCC 86 83.8 1.0 0.8–1.3
Total cholangiocarcinoma 42 20.6 2.0 1.5–2.8
 ICC 28 12.0 2.3 1.6–3.4
 ECC 14 8.6 1.6 0.9–2.7
Ampulla of Vater 12 7.6 1.6 0.8–2.8
Liver only recipients
HCC 30 19.7 1.5 1.0–2.2
Total cholangiocarcinoma 14 4.9 2.9 1.6–4.8
 ICC 10 2.9 3.5 1.7–6.4
 ECC 4 2.0 2.0 0.5–5.0
Ampulla of Vater 1 1.8 0.56 0.01–3.1
Non-liver only recipients
HCC 56 64.1 0.9 0.7–1.1
Total cholangiocarcinoma 28 15.7 1.8 1.2–2.6
 ICC 18 9.2 2.0 1.2–3.1
 ECC 10 6.6 1.5 0.7–2.8
Gallbladder 8 10.0 0.8 0.3–1.6
Ampulla of Vater 11 5.8 1.9 0.9–3.4
Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic 
cholangiocarcinoma; SIR, standardized incidence ratio
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